These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 14584073

  • 21. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
    Voglová J, Poznarová A, Chrobák L, Rabasová J, Beránek M, Moravcová J, Faber E, Klamová H, Cikhart M.
    Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
    [Abstract] [Full Text] [Related]

  • 22. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
    Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C, Mozziconacci MJ, Maarek O, Mossafa H, Auger N, Dastugue N, Talmant P, Van den Akker J, Leonard C, N'Guyen Khac F, Mugneret F, Viguié F, Lafage-Pochitaloff M, Bastie JN, Roux GL, Nicolini F, Maloisel F, Vey N, Laurent G, Recher C, Vigier M, Yacouben Y, Giraudier S, Vernant JP, Salles B, Roussi J, Castaigne S, Leymarie V, Flandrin G, Lessard M, France Intergroupe pour la Leucemie Myeloide Chronique.
    Leukemia; 2004 Aug; 18(8):1340-6. PubMed ID: 15190256
    [Abstract] [Full Text] [Related]

  • 23. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA, Pan Q, Ladanyi M, Steinherz PG.
    Cancer; 2003 Dec 15; 98(12):2643-50. PubMed ID: 14669284
    [Abstract] [Full Text] [Related]

  • 24. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A, Sait SN, Nganga A, Coignet LJ, Barcos M, Baer MR.
    Leuk Res; 2007 Nov 15; 31(11):1589-92. PubMed ID: 17391756
    [Abstract] [Full Text] [Related]

  • 25. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
    Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D, Giles F, Rios MB, Shan J, Arlinghaus R.
    Clin Cancer Res; 2003 Jan 15; 9(1):160-6. PubMed ID: 12538464
    [Abstract] [Full Text] [Related]

  • 26. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM.
    Cancer; 2003 Sep 01; 98(5):888-93. PubMed ID: 12942553
    [Abstract] [Full Text] [Related]

  • 27. [Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease].
    Bulum J, Labar B, Mikulić M, Bogdanić V, Sertić D, Nemet D, Krecak-Gverić V, Kovacević J, Serventi-Seiwerth R, Mrsić-Davidović S, Zadro R, Boban D.
    Lijec Vjesn; 2003 Sep 01; 125(7-8):176-9. PubMed ID: 14692090
    [Abstract] [Full Text] [Related]

  • 28. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
    Marktel S, Marin D, Foot N, Szydlo R, Bua M, Karadimitris A, De Melo VA, Kotzampaltiris P, Dazzi F, Rahemtulla A, Olavarria E, Apperley JF, Goldman JM.
    Haematologica; 2003 Mar 01; 88(3):260-7. PubMed ID: 12651263
    [Abstract] [Full Text] [Related]

  • 29. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 01; 26(1):1-5. PubMed ID: 15946498
    [Abstract] [Full Text] [Related]

  • 30. Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results.
    Holzerová M, Faber E, Veselovská J, Urbánková H, Balcárková J, Rozmanová S, Voglová J, Muzík J, Chroust K, Indrák K, Jarosová M, CAMELIA-Chronic Myeloid Leukaemia Project.
    Cancer Genet Cytogenet; 2009 May 01; 191(1):1-9. PubMed ID: 19389502
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
    Salesi N, Bossone G, Della Longa G, Di Cocco B.
    Minerva Med; 2003 Apr 01; 94(2):71-6. PubMed ID: 12858155
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
    Kantarjian HM, Talpaz M.
    Semin Oncol; 2001 Oct 01; 28(5 Suppl 17):9-18. PubMed ID: 11740802
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
    O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators.
    N Engl J Med; 2003 Mar 13; 348(11):994-1004. PubMed ID: 12637609
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.